Comparative study of chemical approaches to the solid-phase synthesis of a tumor-seeking alpha-MSH analogue by Valldosera, M et al.
Comparative Study of Chemical Approaches to the Solid-Phase
Synthesis of a Tumor-Seeking a-MSH Analogue
Magdalena Valldosera Æ Marta Monso` Æ Catarina Xavier Æ
Paula Raposinho Æ Joa˜o D. G. Correia Æ Isabel Santos Æ
Paula Gomes
Accepted: 30 July 2008 / Published online: 21 August 2008
 Springer Science+Business Media, LLC 2008
Abstract The synthesis of a cyclic melanocortin analogue
(H-pz-bAla-Nle-cyclo[Asp-His-DPhe-Arg-Trp-Lys]-NH2),
where the Boc-protected derivative of a metal-chelating
pyrazolyl ligand (pz) was inserted as N-terminal residue,
was addressed by several different Fmoc/tBu and Boc/Bzl
solid-phase strategies. On-resin cyclization was achieved
immediately following incorporation of Asp, by conden-
sation of the Asp side chain carboxyl with the Lys side
chain primary amine after selective and simultaneous
removal of side chain protecting groups. The success of the
synthesis was highly dependent on the chemical strategy
employed, with Boc/Bzl chemistry giving the best results.
On the light of our findings, Fmoc/tBu strategies are not
advantageous for the solid-phase synthesis of this particular
type of lactam-bridged peptides. Last, but not least, the
target peptide was recently found to have promising tumor-
seeking properties (J Biol Inorg Chem 13:449–459, 2008).
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Introduction
Intramolecular cyclization has been demonstrated to
improve biological properties of bioactive peptides, in
many cases allowing improving bioavailability, metabolic
stability and/or selectivity for a given receptor (Al-Obeidi
et al. 1989; Arnott et al. 2006; Besser et al. 2000a, b;
Charpentier et al. 1989; Che and Marshall 2006; Flora
et al. 2005; Gilon et al. 1991; Gomes et al. 2001; Kera-
mida et al. 2006; Kaul et al. 2005; Liederer et al. 2006;
Nielsen et al. 2005; Norgren et al. 2006; Poteau and
Trinquier 2005; Reissmann and Imhof 2004). Classically,
cyclic peptides have been prepared exclusively in solution
or through on-resin assembly of the linear precursor fol-
lowed by cyclization in solution, but these procedures are
affected by undesired cyclo-oligomerization that occurs
even at high dilutions. Hence, the pseudo-dilution effect on
solid-phase peptide synthesis (SPPS) has given a prominent
role to solid-phase cyclization, i.e., performance of the
cyclization step while the peptide is still attached to the
resin (Rovero 2000).
We are interested in the development of novel cyclic
analogues of a-melanocyte-stimulating hormone (a-MSH)
that can be radio-labeled with 99mTc for detection of MC1
receptors over-expressed in melanoma. In view of the
excellent results with melanotan II peptide (MTII) (Holder
and Haskell-Luevano 2004), we have recently proposed
peptide pz-bAla-MTII as a promising candidate for that
purpose (Raposinho et al. 2008a). pz-bAla-MTII is a side
chain-to-side chain cyclic homodetic peptide whose N-
terminal residue (pz) is a bifunctional chelating agent
required for capture of 99mTc and available in our lab as the
Boc-protected derivative (Raposinho et al. 2008b). The
synthesis of pz-bAla-MTII can be envisaged by an entirely
solid-phase methodology where normal attachment of the
peptide C-terminal residue to the solid support is followed
by assembly of the amino acid linear sequence, after which
the Lys and Asp side chain protecting groups are selec-
tively removed and lactamization is promoted. Finally, the
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cyclic peptide could be detached from the solid support
according to usual procedures.
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βAla-Nle-cyclo[Asp-His-DPhe-Arg-Trp-Lys]-NH2
O
pz-βAla-MTII
Schiller et al. (1985) have been the first to follow such a
strategy, using N-Fmoc protected amino acids with Bzl
side chain protecting groups, except in the case of the
carboxyl and amine functions that were to be cyclized,
which were protected with the tBu and Boc groups,
respectively. The final cyclic products were obtained after
slow cyclization steps followed by HF cleavage. The same
authors have further described the synthesis of more
demanding cyclic peptides, based on Boc/Bzl and Fmoc/
Bzl chemistries (Schiller et al. 1988). Another earlier
approach for the synthesis of side chain-to-side chain ho-
modetic peptides, described by Felix et al. (1988) was
based on the Boc/Bzl chemistry where base-labile Fmoc/
OFm groups (Boc/Bzl/Fm) were used for orthogonal pro-
tection of side chains that would be used for intramolecular
cyclization. In the 1990s, Hruby and co-workers addressed
the synthesis of a-MSH analogues like pz1-bAla-MTII
following the above approaches (Al-Obeidi et al. 1989;
Sugg et al. 1988; Hadley et al. 1997; Hruby et al. 1995).
To avoid HF cleavage, Fmoc/tBu strategies based on allyl
chemistry (Fmoc/tBu/All) were later proposed by Lyttle
and Hudson (1992), and the present diversity of available
building blocks for Fmoc/tBu SPPS provides other options,
such as the hydrazine-labile ivDde/Dmab (Fmoc/tBu/
Dmab) (Chan et al. 1995; Chhabra et al. 1998) or the
hyper-acid labile Mtt/2-PhiPr (Fmoc/tBu/PhiPr) (Aletras
et al. 1995; Yue et al. 1993) groups for selective protection
of the amine/carboxyl side chains that will form the lactam
bridge. We wish to report our comparative study on the
application of four different chemical approaches to the
synthesis of peptide pz-bAla-MTII, based on diverse
orthogonal protection schemes in both Boc/Bzl and Fmoc/
tBu SPPS.
Materials and Methods
Chemicals
All amino acids, coupling agents, handles and resins were
purchased to NovaBiochem (VWR International-Lisbon,
Portugal). All other chemicals and solvents were from
Sigma-Aldrich (Lisbon, Portugal). Boc-pz was prepared in-
house as previously described (Raposinho et al. 2008b).
Instrumentation and Chromatographic Conditions
Mass spectra were acquired either by MALDI-TOF or ESI-
MS techniques on an Applied Biosystems 4700 Proteomics
Analyzer or a LCQ DECA XP ThermoFinnigan spec-
trometer, respectively. UV–vis analysis was done on a
Helios Gamma spectrometer from Thermo Scientific.
Reversed-phase high performance liquid chromatography
(RP-HPLC) analyses were run on either a Beckman System
Gold or a Waters 712, using a Waters Symmetry C-18
column (5 lm; 150 9 3.9 mm) and an elution gradient of
5 ? 95% B over 30 min, at 1 ml/min flow, with detection
at 220 nm. HPLC solvents were A = H2O ? 0.045%TFA,
B = MeCN ? 0.036%TFA. Crude mixtures containing the
target peptide as main product were purified by RP-HPLC
using a semi-preparative Hypersil C-18 column (10 lm;
250 9 8 mm).
Preparation of the Fmoc-Rink-MBHA Resin for Fmoc/
tBu Approaches
Resin MBHA with a functionalization of 0.62 mmol/g was
coupled to the Fmoc-Rink linker (1.5 eq) by employment
of N,N0-diisopropylcarbodiimide (DIPCDI, 1.5 eq) as
coupling agent. Unreacted amino groups were blocked by
acetylation with acetic anhydride (20 eq) in the presence of
N-ethyl-N,N0-diisopropylamine (DIEA, 20 eq) and final
funcionalization of the Fmoc-Rink-MBHA resin thus
obtained was of 0.30 mmol/g, as determined by UV–Vis
spectrometry (Gude et al. 2003).
Peptide Synthesis
(a) 1st Approach: The linear sequence of pz-bAla-MTII
was assembled in the C ? N direction up until the incor-
poration of Boc-pz-OH, using TBTU (3 eq) and DIEA
(6 eq) to promote amino acid couplings and 20% piperi-
dine in N,N-dimethylformamide (DMF) for Fmoc-removal
cycles. FmocAsp(ODmab)OH and FmocLys(ivDde)OH
were used for orthogonal removal of their side chain pro-
tecting groups prior to the cyclization step (Aletras et al.
1995; Chan et al. 1995). The completion of each coupling
step was confirmed by means of the Kaiser test (Kaiser
et al. 1970) and, whenever amino acid coupling was not
quantitative, a re-coupling step was done using the same
molar equivalents as above. Deprotection cycles were also
monitored by the Kaiser test and repeated whenever nee-
ded. The resin was then treated with 2% hydrazine in DMF
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(10 min) for simultaneous removal of the Dmab and ivDde
side chain protecting groups. Condensation of the Asp and
Lys side chains to form the intramolecular lactam bridge
was then carried out by using TBTU (6 eq), DIEA (12 eq)
and 1-hydroxybenzotriazole (HOBt, 6 eq) for 2 h (negative
Kaiser test). Full deprotection and cleavage of the final
peptide from the solid support was performed by treatment
of the peptidyl-resin with trifluoroacetic acid containing
2.5% H2O and 2.5% triisopropylsilane (TFA/H2O/TIS
95:2.5:2.5). The crude product was analyzed by RP-HPLC
and MALDI-TOF MS and found to be a complex mixture
that did not contain the target peptide (cf. Table 1).
(b) 2nd Approach: The synthesis was carried out as in
(a), but using larger excess of FmocAAOH (6 eq), TBTU
(6 eq) and DIEA (12 eq) for the coupling steps and
either 50% piperidine in N-methylpirrolidone (NMP) or
20% piperidine ? 5% 1,8-diazabicyclo-[5.4.0]undec-7-ene
(DBU) in DMF for difficult deprotection steps. Once Boc-
pz-OH was incorporated in the peptidyl-resin, this was
repeatedly treated with 2% hydrazine in DMF until no
increase on absorption at 290 nm, due to the indazole by-
product arising from protecting group removal, was
detected (cf. Results and Discussion) (Johnson et al. 2000).
The resin was then washed with 20% DIEA in DMF/water
90:10 to overcome eventual problems with sluggish
cleavage of the aminobenzyl moiety in the course of Dmab
removal (cf. Results and Discussion). Condensation of the
Asp and Lys side chains to form the intramolecular lactam
bridge was carried out by using PyBOP (4 eq), DIEA
(8 eq), and HOBt (4 eq) and allowing the reaction to
proceed until a negative Kaiser test was obtained (*72 h).
Full deprotection and cleavage of the final peptide from the
solid support was performed as before. The crude product
was analyzed by RP-HPLC and MALDI-TOF MS and
found to be a complex mixture that only contained traces of
the target peptide (cf. Table 1).
(c) 3rd Approach: The synthesis was carried out as
described for (b), with the difference that Dmab and
ivDde removal and subsequent lactamization were carried
out immediately after incorporation of FmocAsp(ODmab)
OH, i.e., prior to Fmoc-removal and further assembly
of the N-terminal segment pz-bAla-Nle. Simultaneous
removal of the Dmab and ivDde protecting groups were
carried out by treating the peptidyl-resin with a freshly
prepared mixture of hydroxylamine hydrochloride and
imidazole in NMP, according to Bradley and co-workers
(Dı´az-Mocho´n et al. 2006). The cyclization step was done
using PyBOP (8 eq), DIEA (16 eq), and HOBt (8 eq) and
allowing the reaction to proceed for *36 h (negative
Kaiser test). The N-terminal segment was normally
assembled thereafter. Full deprotection and cleavage of
the final peptide from the solid support was performed as
before. The crude product was analyzed by RP-HPLC and
MALDI-TOF MS and found to contain the target peptide
as the major product (cf. Table 1) that was isolated by
semi-preparative RP-HPLC and quantitated by UV–vis.
Yield: 27%; calcd m/z for [M]? 1302.75; found: 1303.62
[M ? H]?.
A portion of the peptidyl-resin was cleaved prior to
incorporation of the N-terminal pyrazolyl ligand Boc-pz,
Table 1 Summary of MS data on crude products obtained on the synthetic approaches targeted at pz-bAla-MTIIa and based on the ivDde/
ODmab side chain protection scheme
Synthetic approach m/z Observed Relative abundance/% Compatible peptide fragment
1st 1190.47 7 pz-bAla-cyclo[AspHisDPheArgTrpLys]-NH2
1511.64 35 pz-bAlaNleAsp(ODmab)-DPheArgTrpLys-NH2
1597.72 10 -bAlaNleAspHisDPheArg(Pbf)TrpLys(ivDde)-NH2
1641.76 100 -bAlaNleAsp(ODmab)His(Trt)DPheArgTrpLys-NH2
2nd 695.73 100 -bAla-His-ArgTrpLys-NH2
772.47 38 HisDPheArgTrpLys-NH2
798.60 47 -Nlecyclo[AspHisDPheArg-Lys]-NH2
880.13 20 pz-bAlaNleAsp-ArgTrp-NH2
982.67 15 -Nlecyclo[AspHisDPheArgTrpLys]-NH2
1303.80 10 pz-bAla-MTII
1388.80 30 pz-bAlaNleAspHisDPheArgTrpLys(ebAla)-NH2
1597.67 35 bAlaNleAspHisDPheArg(Pbf)TrpLys(ivDde)-NH2
3rd 1303.62 100 pz-bAla-MTII
1466.73 44 pz-bAlaNleAsp(ODmab)HisDPheArg-Lys-NH2
1580.36 25 pz-NleAsp(ODmab)HisPheArgTrpLys-NH2
1744.67 15 pz-bAla-Asp(ODmab)HisDPheArgTrpLys(ivDde)-NH2
a pz-bAla-MTII: pz-bAlaNlecyclo[AspHisDPheArgTrpLys]; calcd. m/z = 1303.75 ([M ? H]?)
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showing that this final step did not much affect the quality
of the final product. Therefore, given the laborious proce-
dure behind the production of Boc-pz, all subsequent
synthetic approaches (4th to the 6th), tested for compari-
son, excluded coupling of Boc-pz and thus were terminated
after incorporation of bAla.
(d) 4th Approach: The synthesis was carried out as
described in (c), but using FmocAsp(O-2-PhiPr)OH and
FmocLys(Mtt)OH, instead of the previously referred Asp
and Lys derivatives, and cleaving for analysis prior to
incorporation of Boc-pz. Simultaneous cleavage of the Asp
and Lys side chain protecting groups was carried out after
FmocAsp(O-2-PhiPr)OH incorporation, by treatment with
1% TFA in dichloromethane (DCM) containing 5% TIS
(3 9 2 min). Also, FmocHis(Boc)OH was used instead of
FmocHis(Trt)OH, to prevent any premature leaching of
Trt ?tul?> groups in the course of 2-PhiPr and Mtt removal.
Cyclization, done as in (c), did not reach completion
after 72 h and was repeated using 1-ethyl-3-(3-dimethyl-
aminopropyl)carbodiimide hydrochloride (EDC, 4 eq), N-
hydroxysuccinimide (HOSu, 4 eq) and DIEA (4 eq) until
negative Kaiser test (*6 h). After full deprotection and
cleavage of the final peptide, the crude product was ana-
lyzed by RP-HPLC and MALDI-TOF MS and found to be
a mixture containing the target peptide as a secondary
product.
(e) 5th Approach: The synthesis was carried out as
described in (c), but using FmocAsp(O-All)OH and Fmoc-
Lys(Alloc)OH instead of the previously referred Asp and
Lys derivatives. Simultaneous cleavage of the Asp and Lys
side chain protecting groups was carried out as described
for similar peptides (Grieco et al. 2006), i.e., the allyl and
alloc protecting groups were removed with a catalytic
amount of Pd(PPh3)4 in the presence of triethylsilane (TES)
and under inert atmosphere (argon). TES was used to
protect Trp and Arg residues from alkylation by cations
produced on the cleavage step. Lactamization was then
promoted as previously described in (c). After full assem-
bly of the peptide and its cleavage from the resin, the crude
product was analyzed by RP-HPLC and MALDI-TOF MS
and found to be a complex mixture containing the target
peptide as a minor product.
(f) 6th Approach: The synthesis was carried out also by
Boc/Bzl chemistry, on a MBHA resin with a functionali-
zation of 0.62 mmol/g. Boc-Asp(O-Fm)OH and BocLys-
(Fmoc)OH were used and their side chain protecting groups
removed immediately after incorporation of Asp by the
usual treatment with 20% piperidine in DMF. Cyclization
was subsequently carried out as already described and final
cleavage of the fully deprotected peptide from the resin was
done by acidolysis with liquid anhydrous HF. The crude
product was mainly composed by the target peptide, as
concluded from RP-HPLC and MALDI-TOF MS analysis.
Results and Discussion
As described in Materials and Methods, and depicted on
Scheme 1, six SPPS approaches were tested aiming at syn-
thesizing the cyclic lactam peptide pz-bAla-MTII. Three of
them were based on the Fmoc/tBu/Dmab chemistry, i.e.,
used FmocLys(ivDde)OH and FmocAsp(ODmab)OH as
selectively protected derivatives for orthogonal removal of
their side chain protecting groups prior to the cyclization
step and differed in the experimental procedures regarding
coupling and deprotection conditions (a) and (b) or con-
cerning the moment at which the cyclization step was carried
out in the course of the solid-phase synthesis (c). As shown
in Table 1, MS analysis of the crude products showed that
the target peptide was only obtained as major product in the
last case, i.e., when selective deprotection of the Lys and
Asp side chain protecting groups and subsequent lactami-
zation were carried out immediately after FmocAsp
(ODmab)OH incorporation, i.e., before assembly of the
N-terminal pz-bAla-Nle segment.
A brief analysis of Table 1 can illustrate the path fol-
lowed until peptide pz-bAla-MTII was successfully
synthesized. The first approach led to acyclic peptides still
bearing the Dmab side chain protecting group as major
products. This encouraged us to try a second approach
where not only the coupling and Fmoc-removal conditions
were stronger to avoid deletions observed in the previous
approach, but also, and more relevantly, the Dmab/ivDde
removal cycle with hydrazine was carried out with addi-
tional precautions to ensure complete removal of the Dmab
group. This group is removed in a two-step reaction where
hydrazine firstly cleaves the ivDde moiety, which is
released as an indazole by-product that can be detected at
290 nm, after which the p-amino benzyl ester suffers
spontaneous cleavage to give the free carboxyl group
(Scheme 2) (Chan et al. 1995; Chhabra et al. 1998; John-
son et al. 2000).
Sluggish removal of Dmab has been reported in some
cases and washing the peptidyl-resin with 20% DIEA in
DMF/water 90:10 has been suggested as a means to obviate
this problem (Johnson et al. 2000). Thus we have carried
out several cycles of hydrazine treatment, while monitoring
the absorbance of the liquid phase eluted after each cycle,
and only carried forward when indazole release was no
longer detected. These procedures did not lead to success,
as the target peptide was only observed as a minor product
in a highly complex crude mixture where main products
arose from multiple deletions. The obtention of truncated
sequences as major products in such a short sequence is
possibly due to bulky side chain protecting groups that
interfere with the efficiency of both coupling and depro-
tection steps. Also, Fmoc-removal conditions may have
been too harsh in some instances, as the observation of a
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species at m/z 1388.80 (Table 1) is compatible with the
uncyclized sequence having over-incorporation of a b-Ala;
this was most probably due to the fact that ivDde, though
more stable to Fmoc-removal conditions than Dde (Chh-
abra et al. 1998), is not 100% orthogonal with harsher
Fmoc deprotection cycles (extended times, increased
piperidine and/or DBU concentrations, etc.). It is worth
mentioning that aspartimide formation was not evident,
despite the use of Dmab has been claimed to increase the
occurrence of such problem (Johnson et al. 2000).
In view of the above results, cyclization at an earlier
stage, i.e., immediately after incorporation of Fmo-
cAsp(ODmab)OH, seemed advantageous, as ivDde would
be exposed to fewer Fmoc-deprotection cycles and the
bulky Dmab and ivDde groups would be removed sooner,
possibly allowing for a more efficient assembly of the
peptide’s N-terminal stretch. This strategy, however, is not
compatible with the use of hydrazine for Dmab/ivDde
removal, as Fmoc is not stable to hydrazine and would
be simultaneously cleaved. Nonetheless, Bradley and
pz-βAla-Nle-cyclo [Asp-His-DPhe-Arg-Trp-Lys]-NH2
pz-βAla-MTII
Boc-pz-βAla-Nle-Asp-His-DPhe-Arg-Trp-Lys-NH2
Dmab ivDde
Fmoc-Asp-His-DPhe-Arg-Trp-Lys-NH2
Dmab ivDde
Fmoc-Asp-His-DPhe-Arg-Trp-Lys-NH2
PhiPr Mtt
Fmoc-Asp-His-DPhe-Arg-Trp-Lys-NH2
All Alloc
Boc-Asp-His-DPhe-Arg-Trp-Lys-NH2
Fm Fmoc
1: (i), (ii)
2: (i), (iii)
cyclo [Asp-His-DPhe-Arg-Trp-Lys]-NH2
3: (iv), (v)
4: (vi), (v), (vii)
5: (viii), (v)
βAla-Nle-cyclo[Asp-His-DPhe-Arg-Trp-Lys]-NH2
6: (ix), (v)
(x)
(xi)
Scheme 1 Synthetic strategies towards the target peptide pz-bAla-
MTII. 1 and 2, Fmoc/tBu/Dmab with cyclization step after incorpo-
ration of Boc-pz: (i) 2% hydrazine in DMF, (ii) TBTU/DIEA/HOBt
6:12:6 eq., (iii) PyBOP/DIEA/HOBt 4:8:4 eq.; 3, Fmoc/tBu/Dmab
with cyclization step after incorporation of Fmoc-Asp(ODmab)-OH:
(iv), NH2OH.HCl/imidazole in NMP/CH2Cl2; (v) PyBOP/DIEA/
HOBt 8:16:8 eq.; 4, Fmoc/tBu/PhiPr approach: (vi) 1% TFA/DCM;
(vii) additional lactamization step using EDC/HOSu/DIEA 4:4:4 eq.;
5, Fmoc/tBu/All approach: (viii) Pd(PhPh3)4, TES, inert atmosphere;
6, Boc/Bzl/Fm approach: (ix) 20% piperidine/DMF; (x) normal
assembly of the remaining amino acids; (xi) final incorporation of the
Boc-pz ligand (not done in all cases)
R O
O
NH O
O
ODmab
ivDde
R O
O
NH2
R OH
O
NH+
HN N
NH2NH2
O
Scheme 2 Removal of Dmab with concomitant release of the ivDde-derived indazole by-product, detectable at 290 nm; adapted from (Johnson
et al. 2000)
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co-workers have recently described a different cleaving
cocktail, based on hydroxylamine hydrochloride and imid-
azole, for selective removal of Dde in the presence of the
Fmoc-protecting group (Dı´az-Mocho´n et al. 2006). Hence,
it was expectable that both ivDde and Dmab would be
selectively cleaved under similar conditions, which was
tested in our 3rd synthetic approach. Indeed, as mentioned
before, this approach led to the target peptide as one of the
main products, even though the crude mixture still possessed
three other relevant products, all of them having the Dmab
group unremoved (Table 1). Consequently, we decided to
further investigate whether alternative methodologies
would lead to better results. At this stage, we thought that a
comparative study of methodologies to prepare the peptide
precursor not incorporating the N-terminal pz moiety
(bAla-MTII) would be preferable, as preparation of Boc-pz
is quite laborious. Thus, the synthesis of bAla-MTII was
comparatively studied by four different solid-phase meth-
odologies, as described in sub-sections (c) to (f), three of
them by Fmoc/tBu chemistry based on different Asp and
Lys side chain protection schemes (ivDde/ODmab, Mtt/
OPhiPr, and Alloc/OAll) and one by Boc/Bzl/Fm chemistry.
This allowed us to conclude that the best synthetic approach
to peptide bAla-MTII was that based on Boc/Bzl/Fm
chemistry, as the crude product obtained was of higher
quality (Fig. 1a, c), being immediately followed by the one
obtained through application of the Fmoc/tBu/PhiPr strat-
egy (Fig. 1b, d). The classical Fmoc/tBu/All protection
scheme led to crude mixtures of lower quality, with the
target peptide accompanied by substantial amounts of other
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A BFig. 1 Crude products from the
two best approaches to the
synthesis of bAla-MTII, as
analyzed by RP-HPLC
(retention time of the target
peptide = 8.58 min)–(a) Fmoc/
tBu/PhiPr approach; (b) Boc/
Bzl/Fm approach; and by
MALDI-TOF MS–(c) Fmoc/
tBu/PhiPr approach; (d) Boc/
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by-products, whereas the Fmoc/tBu/Dmab strategy was the
worst of all.
Finally, it is worth mentioning that several additional
experiments were conducted where either resin or cycliza-
tion conditions were varied, but never led to better results.
For instance, the use of the PEG-based resin ChemMatrix
(Garcı´a-Martı´n et al. 2006) instead of MBHA did not pro-
vide any improvement in the Fmoc/tBu strategies used (data
not shown), whereas the use of current coupling conditions
(usual carbodiimides, TBTU/DIEA) instead of one-step
PyBOP/DIEA or two-step PyBOP/DIEA ? EDC/HOSu/
DIEA approaches to on-resin lactamization usually led to
too sluggish reactions. Also interesting was the consistent
observation, in several of the Fmoc/tBu/Dmab-based syn-
theses assayed, of a major product at m/z 1259. This species
could not be easily identified as an ‘‘expectable’’ by-prod-
uct, being attributed to a combination of non-removal of
ivDde with Asp/isoAsp conversion during the ‘‘cyclization’’
step, as proposed in Scheme 3.
Concluding Remarks
As far as we know, and concerning the solid-phase syn-
thesis of a-MSH cyclic analogues inspired in melanotan-II
(Dorr et al. 1996), this is the first work where Fmoc/tBu
strategies with orthogonal protection schemes other than
those based on allyl chemistry were used. As previously
mentioned, the pioneer works by Hruby and co-workers
were based in Boc/Bzl strategies (Al-Obeidi et al. 1989;
Sugg et al. 1988; Hadley et al. 1997; Hruby et al. 1995)
that were later employed by other researchers (Bednarek
et al. 2001). In the late 1990s, Schaaper et al. (1998)
reported the synthesis of cyclic a-MSH analogues using
Fmoc chemistry, but nothing is described in this paper
about the protection schemes used, as their work was
mainly focused on the efficiency of the cyclization step.
Very recently, Hruby and co-workers have also addressed
the synthesis of cyclic c-MSH analogues using Fmoc
chemistry, but in this case a head-to-side chain lactam
bridge was built between an N-terminal Nle and a C-ter-
minal Glu after selective deprotection of its Glu(OAllyl)
precursor (Mayorov et al. 2006).
Overall, our findings point to the fact that Boc/Bzl/Fm
chemistry is still the best synthetic approach to MTII
analogues, ever since its first application to such peptides
by Hruby’s group. It is true that the panoply of selectively-
protected Lys and Asp derivatives commercially available
for Fmoc/tBu-based approaches to on-resin lactamization
widens the universe of alternative tools towards the
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NH
NH
O
O
HN
H2N
O
NH
Fmoc
O
O
OH
Asp/isoAsp conversion
(desired cyclization impeded)
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ivDde
assembly of t he N-terminal
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Scheme 3 Proposed side-reaction behind the appearance, on some Fmoc/tBu/Dmab-based syntheses, of a major product with m/z 1259 (see text)
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synthesis of homodetic cyclic peptides. However, in our
particular case, only the Fmoc/tBu/PhiPr could almost
reach the efficiency of the Boc/Bzl/Fm synthesis, having
the additional disadvantage of not being economically
attractive.
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